Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parecoxib (parecoxib sodium).

S M Cheer1, K L Goa

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Parecoxib, an injectable COX-2 inhibitor, effectively manages postoperative pain, showing efficacy comparable to ketorolac and superiority over morphine. It also demonstrates a better gastrointestinal safety profile than ketorolac.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Follitropin alpha in infertility: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Pain Management
  • Gastroenterology

Background:

  • Parecoxib is an injectable prodrug of valdecoxib, a selective cyclo-oxygenase-2 inhibitor.
  • Selective COX-2 inhibitors offer potential advantages in pain management with improved gastrointestinal safety.
  • Understanding parecoxib's efficacy and safety profile is crucial for its clinical application.

Purpose of the Study:

  • To evaluate the analgesic efficacy of parecoxib compared to placebo, ketorolac, and morphine in various surgical settings.
  • To assess the gastrointestinal safety of parecoxib in comparison to ketorolac and placebo.
  • To determine the overall tolerability and adverse event profile of parecoxib.

Main Methods:

  • Multiple well-controlled trials were conducted involving patients undergoing dental, gynecological, and orthopedic surgery.

Related Experiment Videos

  • Intravenous (IV) or intramuscular (IM) parecoxib was administered at various doses and compared to placebo, ketorolac, and IV morphine.
  • Gastrointestinal mucosal effects were assessed in healthy volunteers using endoscopic evaluation of erosions and ulcers.

    • Main Results:

    • Parecoxib demonstrated analgesic activity superior to placebo and similar to ketorolac in dental pain.
    • Following gynecological and orthopedic surgery, parecoxib showed efficacy comparable to ketorolac and superior to morphine.
    • Parecoxib produced significantly fewer gastrointestinal erosions/ulcers than ketorolac, with effects similar to placebo on upper gastrointestinal mucosa.

    Conclusions:

    • Parecoxib provides effective analgesia for various postoperative pain conditions.
    • Parecoxib exhibits a favorable gastrointestinal safety profile compared to ketorolac.
    • Parecoxib is well-tolerated and represents a viable option for postoperative pain management.